Close Menu

thyroid cancer

Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.

The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.

Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.

Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.

When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.

The diagnostics company said the number of tests accessioned during the quarter grew 60 percent year over year.

The test analyzes microRNA expression in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.

The test is used in conjunction with the firm's ThyGenX oncogene panel to assess fine needle aspiration samples from indeterminate thyroid nodules.

Researchers and clinicians attempting to select targeted therapies must take sample heterogeneity into account.

Through studies of individuals with an inherited cancer predisposition syndrome, researchers identified germline mutations contributing to sporadic thyroid cancer as well.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.